STOCK TITAN

[Form 4] AtriCure, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 30 June 2025, AtriCure, Inc. (ATRC) Chief Legal Officer Karl S. Dahlquist acquired 822 common shares through the company’s 2018 Employee Stock Purchase Plan (ESPP). The purchase price was $25.84, reflecting the plan’s 15% discount from the closing price of $30.40 on 2 January 2025, the first trading day of the offering period. Following the transaction, Dahlquist directly owns 68,551 ATRC shares. The Form 4 was signed on 2 July 2025 and indicates a routine, plan-based acquisition with no shares sold or disposed of.

Il 30 giugno 2025, Karl S. Dahlquist, Chief Legal Officer di AtriCure, Inc. (ATRC), ha acquistato 822 azioni ordinarie tramite il Piano di Acquisto Azionario per Dipendenti 2018 (ESPP) della società. Il prezzo di acquisto è stato di 25,84 $, corrispondente al 15% di sconto rispetto al prezzo di chiusura di 30,40 $ del 2 gennaio 2025, primo giorno di negoziazione del periodo di offerta. Dopo questa operazione, Dahlquist detiene direttamente 68.551 azioni ATRC. Il modulo Form 4, firmato il 2 luglio 2025, indica un acquisto di routine basato sul piano senza azioni vendute o cedute.

El 30 de junio de 2025, Karl S. Dahlquist, Director Legal de AtriCure, Inc. (ATRC), adquirió 822 acciones comunes a través del Plan de Compra de Acciones para Empleados 2018 (ESPP) de la compañía. El precio de compra fue de $25.84, reflejando un descuento del 15% sobre el precio de cierre de $30.40 del 2 de enero de 2025, primer día de negociación del período de oferta. Tras la transacción, Dahlquist posee directamente 68,551 acciones ATRC. El Formulario 4 fue firmado el 2 de julio de 2025 e indica una adquisición rutinaria basada en el plan sin acciones vendidas o transferidas.

2025년 6월 30일, AtriCure, Inc.(ATRC)의 최고 법률 책임자 Karl S. Dahlquist가 회사의 2018년 직원 주식 구매 계획(ESPP)을 통해 822주 보통주를 취득했습니다. 매입 가격은 $25.84로, 2025년 1월 2일 첫 거래일 종가 $30.40에서 15% 할인된 가격입니다. 거래 후 Dahlquist는 직접 68,551주 ATRC 주식를 보유하게 되었습니다. Form 4는 2025년 7월 2일에 서명되었으며, 일상적인 계획 기반 취득으로 주식 매도나 처분은 없음을 나타냅니다.

Le 30 juin 2025, Karl S. Dahlquist, Chief Legal Officer d'AtriCure, Inc. (ATRC), a acquis 822 actions ordinaires via le Plan d'Achat d'Actions Employés 2018 (ESPP) de la société. Le prix d'achat était de 25,84 $, reflétant une remise de 15 % par rapport au cours de clôture de 30,40 $ du 2 janvier 2025, premier jour de négociation de la période d'offre. Suite à cette transaction, Dahlquist détient directement 68 551 actions ATRC. Le formulaire 4, signé le 2 juillet 2025, indique une acquisition de routine basée sur le plan sans actions vendues ou cédées.

Am 30. Juni 2025 erwarb Karl S. Dahlquist, Chief Legal Officer von AtriCure, Inc. (ATRC), 822 Stammaktien über den Mitarbeiteraktienkaufplan (ESPP) von 2018 des Unternehmens. Der Kaufpreis betrug 25,84 $, was einem 15%igen Rabatt auf den Schlusskurs von 30,40 $ am 2. Januar 2025, dem ersten Handelstag des Angebotszeitraums, entspricht. Nach der Transaktion besitzt Dahlquist direkt 68.551 ATRC-Aktien. Das Formular 4 wurde am 2. Juli 2025 unterzeichnet und weist auf einen routinebasierten, planmäßigen Erwerb hin, ohne dass Aktien verkauft oder veräußert wurden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine ESPP purchase of 822 shares by ATRC CLO; immaterial to valuation, signals ongoing insider participation.

The reported acquisition is small—about $21 k—and executed under AtriCure’s ESPP, a non-discretionary program that automatically enrolls eligible employees. Because the transaction adds roughly 1.2% to the officer’s existing 68.5 k-share position and involves no open-market buying or selling, it is unlikely to influence market perception or the firm’s risk profile. Such plan-based purchases are generally viewed as neutral: they confirm continued employee alignment but do not constitute a deliberate vote of confidence in the stock. Therefore, I classify the filing as non-impactful for investors.

Il 30 giugno 2025, Karl S. Dahlquist, Chief Legal Officer di AtriCure, Inc. (ATRC), ha acquistato 822 azioni ordinarie tramite il Piano di Acquisto Azionario per Dipendenti 2018 (ESPP) della società. Il prezzo di acquisto è stato di 25,84 $, corrispondente al 15% di sconto rispetto al prezzo di chiusura di 30,40 $ del 2 gennaio 2025, primo giorno di negoziazione del periodo di offerta. Dopo questa operazione, Dahlquist detiene direttamente 68.551 azioni ATRC. Il modulo Form 4, firmato il 2 luglio 2025, indica un acquisto di routine basato sul piano senza azioni vendute o cedute.

El 30 de junio de 2025, Karl S. Dahlquist, Director Legal de AtriCure, Inc. (ATRC), adquirió 822 acciones comunes a través del Plan de Compra de Acciones para Empleados 2018 (ESPP) de la compañía. El precio de compra fue de $25.84, reflejando un descuento del 15% sobre el precio de cierre de $30.40 del 2 de enero de 2025, primer día de negociación del período de oferta. Tras la transacción, Dahlquist posee directamente 68,551 acciones ATRC. El Formulario 4 fue firmado el 2 de julio de 2025 e indica una adquisición rutinaria basada en el plan sin acciones vendidas o transferidas.

2025년 6월 30일, AtriCure, Inc.(ATRC)의 최고 법률 책임자 Karl S. Dahlquist가 회사의 2018년 직원 주식 구매 계획(ESPP)을 통해 822주 보통주를 취득했습니다. 매입 가격은 $25.84로, 2025년 1월 2일 첫 거래일 종가 $30.40에서 15% 할인된 가격입니다. 거래 후 Dahlquist는 직접 68,551주 ATRC 주식를 보유하게 되었습니다. Form 4는 2025년 7월 2일에 서명되었으며, 일상적인 계획 기반 취득으로 주식 매도나 처분은 없음을 나타냅니다.

Le 30 juin 2025, Karl S. Dahlquist, Chief Legal Officer d'AtriCure, Inc. (ATRC), a acquis 822 actions ordinaires via le Plan d'Achat d'Actions Employés 2018 (ESPP) de la société. Le prix d'achat était de 25,84 $, reflétant une remise de 15 % par rapport au cours de clôture de 30,40 $ du 2 janvier 2025, premier jour de négociation de la période d'offre. Suite à cette transaction, Dahlquist détient directement 68 551 actions ATRC. Le formulaire 4, signé le 2 juillet 2025, indique une acquisition de routine basée sur le plan sans actions vendues ou cédées.

Am 30. Juni 2025 erwarb Karl S. Dahlquist, Chief Legal Officer von AtriCure, Inc. (ATRC), 822 Stammaktien über den Mitarbeiteraktienkaufplan (ESPP) von 2018 des Unternehmens. Der Kaufpreis betrug 25,84 $, was einem 15%igen Rabatt auf den Schlusskurs von 30,40 $ am 2. Januar 2025, dem ersten Handelstag des Angebotszeitraums, entspricht. Nach der Transaktion besitzt Dahlquist direkt 68.551 ATRC-Aktien. Das Formular 4 wurde am 2. Juli 2025 unterzeichnet und weist auf einen routinebasierten, planmäßigen Erwerb hin, ohne dass Aktien verkauft oder veräußert wurden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CARREL MICHAEL H

(Last) (First) (Middle)
7555 INNOVATION WAY

(Street)
MASON OH 45040-9695

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO, & Director
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 A 822(1) A $25.84(2) 707,377 D
Common Stock 9,310 I Held by reporting person's children(3)
Common Stock 2,250 I Held by reporting person's parents(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.
2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.
3. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.
Remarks:
/s/ Allison Walker as Attorney-in-fact for Michael H. Carrel 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Atricure

NASDAQ:ATRC

ATRC Rankings

ATRC Latest News

ATRC Latest SEC Filings

ATRC Stock Data

1.63B
47.75M
3.49%
98.23%
2.91%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MASON